Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects (MOTIVATE 2)
This study has been completed.
First Posted: December 8, 2004
Last Update Posted: May 16, 2012
Information provided by (Responsible Party):